Key facts
- It has raised $5.8M; the latest was Grant ($2.6M) in Feb 2025.
- Notable investors include Creative Destruction Lab, European Innovation Council, Angel Invest, Andrej Henkler, Arve Capital — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Vivalyx
- ·The full record, as it builds
Funding rounds
No funding rounds for Vivalyx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vivalyx
Operator of a patented organ preservation company intended to improve the success of organ transplantation. The company's preservation used static cold storage and machine perfusion, and it aims to increase the vitality and number of donor organs available for transplantation by offering a blood-free alternative, enabling doctors to enhance accessibility to modern techniques, and leading to a lower complication rate for patients in need of a transplant.
- Sector
- Healthcare
- HQ
- Cologne, Germany
- Founded
- 2022
- Employees
- 9
- Website
- vivalyx.com/
- Ownership
- Privately Held (backing)
Vivalyx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vivalyx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vivalyx in its N-PORT filings yet. We sweep new filings monthly.